Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics Inc. (AGRX) is an innovative women's healthcare company focused on developing non-daily contraceptive solutions through its proprietary transdermal technology. This page serves as the definitive source for verified news and official announcements related to product developments, regulatory milestones, and corporate updates.
Investors and healthcare professionals will find comprehensive coverage of Twirla® contraceptive patch updates, financial performance reports, and strategic partnership announcements. Our curated collection ensures timely access to earnings releases, clinical trial progress, and manufacturing updates while maintaining strict adherence to factual reporting standards.
Key information categories include FDA regulatory communications, research advancements in transdermal drug delivery, and market expansion initiatives. All content is rigorously verified to provide reliable insights into the company's position within the women's health sector.
For those monitoring AGRX's progress in contraceptive innovation, we recommend bookmarking this page and checking regularly for essential updates. Our commitment to neutral, accurate reporting makes this your trusted resource for understanding Agile Therapeutics' role in advancing patient-centric healthcare solutions.
Agile Therapeutics, Inc. (OTCQB: AGRX) has announced the completion of its acquisition by Insud Pharma, S.L., a global pharmaceutical group based in Spain. The transaction, approved by Agile shareholders on August 22, 2024, values Agile at approximately $45 million. Former Agile common stockholders will receive $1.52 per share in cash, net of assumed liabilities and estimated transaction costs.
As a result of the acquisition, Agile has combined with Insud Pharma's US subsidiary, Exeltis USA, Inc., expanding their women's health and contraceptive portfolio. Agile will now operate as an indirect subsidiary of Insud and will cease to be listed on any public market, including the OTC QB.
H.C. Wainwright & Co. served as the exclusive financial advisor to Agile Therapeutics, while Morgan, Lewis & Bockius LLP acted as its legal advisor. Insud Pharma and Exeltis USA were advised legally by Loeb & Loeb LLP and RC Law LLP.
Agile Therapeutics has entered a definitive merger agreement with Insud Pharma’s US subsidiary, Exeltis, where Agile shareholders will receive $1.52 per share in cash, representing a 356% premium over the previous closing stock price. The total enterprise value for the transaction is approximately $45 million. The merger is expected to close in Q3 2024, subject to Agile shareholder approval and other customary closing conditions. As part of the agreement, Insud will provide Agile with a line of credit up to $8 million, primarily for inventory purchases. Upon completion, Agile will delist from public markets.
Agile Therapeutics (AGRX) reported significant first quarter 2024 results, showing a 58% increase in net revenue to $5.7 million, driven by a rebound in demand for Twirla, which saw an 18% increase from the prior quarter. Factory sales also grew by 3%. Operating expenses for the quarter were $6.8 million, a 24% increase from Q4 2023 but a decrease of 20% from Q1 2023. The company recorded a GAAP net income of $1.3 million compared to a net loss in the previous quarters. Non-GAAP net loss was $2.9 million, an improvement from previous periods. Cash reserves stood at $2.6 million as of March 31, 2024. Agile's stock began trading on the OTC market in March 2024, and the company is optimistic about the Biden-Harris Administration's steps to improve access to contraceptives.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
